These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16371812)

  • 21. Miliary tuberculosis in a patient with rheumatoid arthritis treated with tumor necrosis factor-alpha inhibitor.
    Aoyama S; Kano Y
    Am J Med Sci; 2023 Sep; 366(3):e38-e39. PubMed ID: 36972732
    [No Abstract]   [Full Text] [Related]  

  • 22. Perioperative management of biologic agents used in treatment of rheumatoid arthritis.
    Mushtaq S; Goodman SM; Scanzello CR
    Am J Ther; 2011 Sep; 18(5):426-34. PubMed ID: 20216205
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in rheumatology: biological agents for the treatment of rheumatoid arthritis, the progression of psoriatic arthritis, autoantibodies in systemic lupus erythematosus.
    Finucane KA; Archer CB
    Clin Exp Dermatol; 2005 Mar; 30(2):201-4. PubMed ID: 15725261
    [No Abstract]   [Full Text] [Related]  

  • 25. The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.
    Hernández MV; Sanmartí R; Cañete JD
    Expert Opin Drug Saf; 2016 May; 15(5):613-24. PubMed ID: 26927029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in targeted therapy: safety of biological agents.
    Keystone EC
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii34-6. PubMed ID: 14532146
    [No Abstract]   [Full Text] [Related]  

  • 27. [The pulmonological manifestations of rheumatoid arthritis].
    Bernscherer G; Karabélyos C; Tarján Z
    Orv Hetil; 2008 Jul; 149(29):1355-61. PubMed ID: 18617467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of lymphoma in patients with RA treated with anti-TNFalpha agents.
    Franklin JP; Symmons DP; Silman AJ
    Ann Rheum Dis; 2005 May; 64(5):657-8. PubMed ID: 15834052
    [No Abstract]   [Full Text] [Related]  

  • 29. Assessing the value of rheumatoid arthritis treatment alternatives: the potential effect of tumor necrosis factor inhibitors.
    Mizutani W
    Manag Care Interface; 2003 Mar; 16(3):44-50, 55. PubMed ID: 12715413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis.
    Boulton JG; Bourne JT
    Rheumatology (Oxford); 2007 Jan; 46(1):178-9. PubMed ID: 16998233
    [No Abstract]   [Full Text] [Related]  

  • 31. The NICE reappraisal of biologics in 2005: what rheumatologists need to know.
    Bansback NJ; Young A; Brennan A
    Rheumatology (Oxford); 2005 Jan; 44(1):3-4. PubMed ID: 15328422
    [No Abstract]   [Full Text] [Related]  

  • 32. Infliximab for rheumatoid arthritis in a patient with tuberculosis.
    Matsumoto T; Tanaka T; Kawase I
    N Engl J Med; 2006 Aug; 355(7):740-1. PubMed ID: 16914717
    [No Abstract]   [Full Text] [Related]  

  • 33. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis.
    Burr ML; Malaviya AP; Gaston JH; Carmichael AJ; Ostör AJ
    Rheumatology (Oxford); 2008 May; 47(5):738-9. PubMed ID: 18375402
    [No Abstract]   [Full Text] [Related]  

  • 34. Tumor Necrosis Factor Inhibitors and Cancer Relapse.
    Ann Intern Med; 2018 Sep; 169(5):. PubMed ID: 30105364
    [No Abstract]   [Full Text] [Related]  

  • 35. Cigarette smoking, TB, and TNF inhibitors.
    Bieber J; Kavanaugh A
    Ann Rheum Dis; 2003 Nov; 62(11):1118-9. PubMed ID: 14583580
    [No Abstract]   [Full Text] [Related]  

  • 36. Dermatomyositis in patients with rheumatoid arthritis during adalimumab therapy.
    Nagashima T; Minota S
    J Rheumatol; 2011 Mar; 38(3):574; author reply 575. PubMed ID: 21362792
    [No Abstract]   [Full Text] [Related]  

  • 37. Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.
    Solomon DH; Mercer E; Kavanaugh A
    Arthritis Rheum; 2012 Jan; 64(1):21-32. PubMed ID: 21898354
    [No Abstract]   [Full Text] [Related]  

  • 38. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
    Kaplan MJ
    Nat Clin Pract Rheumatol; 2005 Dec; 1(2):74-5. PubMed ID: 16932633
    [No Abstract]   [Full Text] [Related]  

  • 39. [TNF-alpha antibody in rheumatoid arthritis. Efficacy-risk relationship is positively evaluated].
    MMW Fortschr Med; 2002 May; 144(20):65. PubMed ID: 12119893
    [No Abstract]   [Full Text] [Related]  

  • 40. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective.
    To KW; Reino JJ; Yoo DH; Tam LS
    Respirology; 2013 Jul; 18(5):765-73. PubMed ID: 23627398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.